<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 293 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page292.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=293">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 293 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 293</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=293"><img src="../thumb/293.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>256 / 2020-04                                                            Anti-Microbials - 18.10
   CoA reduct. inhibit.eg.atorvastatin/cert. glucocorticoids. eg bude-  Drug interactions: Clear.accelerat.by meds. which induc.metabol.,   tacrolimus/ sirolimus/cert.CYP3A4 metabol.HMG-CoA reduct.in-
   sonide, dexamethasone, fluticasone & methyl prednisolone/digox./   clear.inhib.by meds.which inhib. cytochrom.P-450, inhibits CYP2 D6   hibit.eg.atorvastatin/cert. glucocorticoids eg budesonide, dexa-
   carbamazepine/ buspirone/alfentanil/alprazolam/ brotizolam/ mi-  -mediat. metabol., menstr.disturbs.with OC’s.  methasone & methylprednisolone/digox./carbamazepine/ bus-
   dazolam IV/rifabutin/ebastine/ reboxetine/ cilostazol/disopyramide/  TERBINAFINE UNICORN 250, (Unicorn) Sandoz [P/S]  pirone/alfentanil/alprazolam/brotizolam/midazolam IV/ rifabutin/
   eletriptan/ fentanyl/halofantrine & repaglinide, monit.bld. gluc. with   ebastine/reboxetine/ cilostazol/ disopyramide/eletriptan/fentanyl/
   concom.oral hypoglycaem.agents, negat. inotrop.eff., cons. benef./  Terbinafine HCl.  halofantrine & repaglinide, monit.bld.gluc.with concom. oral hy-
                                Indications: Fung.skin infect.caus.by Trichophyton spp., Micro-
   risk in CHF/hist. thereof., HF more freq.with tot.dly.dos.of 400 mg, dis-  poglycaem.agents, excret.in breast milk, maint.ther.for histoplas-
   cont. if neuropathy/CHF develops, sev. neutropen. pts., not recomm.  sporum canis & Epidermophyton floccosum, ringworm where oral   mos to prev. relapse usually reqd.in HIV pts.but optim.treatm. &
   for init.treatm.in pts at imme.risk of system. candidias., hepat./ren.   ther. appropr.due to site/sev./extent of infect., onychomycos.  maint.ther.unknown with stud.ongoing, CHF/ hist. thereof/CHF
   impairm. & cirrhot.pts., Caps also: teratogen.in lab. anim., absorpt.  (S4) TABS, A38/20.2.2/0395  risk fact., discont.if neuropathy develops, absorpt.decr.in HIV pts.
   decr.in HIV pts.with hypochlorhydr., admin. acid neutralis.meds.2   719135-001: 250mg, 14, R344,75  with hypochlorhydr., absorpt.imp.if gastr.acidity reduc. theref.ad-
   hrs.aft., admin.with cola beverage in pts.with achlorhydr., hepat.   Dosage: 250 mg once dly.  min.acid neutralis.meds.2 hrs.aft., admin. with cola beverage in
   funct. impairm, Oral Sol.also: discont.if neuropathy attribut. to ther.  Treatm.durat.varies accord.to indicat.& sev. Tinea pedis: 2-6 wks.   pts.with achlorhydria.
   occurs, not recomm.in pts.at immed. risk of syst.candidias., congenit.  Tinea corporis: 4 wks., Tinea cruris: 2-4 wks. Onychomycos: 6   Drug interactions: Addit.negat.inotrop.effs. with Ca chann.block.,
   abnorm.in animal studies.    wks.-3 mnths.                 metabol.of Ca chan.block. inhibit., absorpt.imp.by decr.gastr.acid.,
                                Contraindications: Imp.liv.funct., safety in pregn. & lactat.not
   Drug interactions: Terfenadine conc.incr.lead.to ser.CV advers.  enzyme induc. agents eg. rifampicin/rifabutin/ carbamazepine /
   effs., enzyme induc.agents eg. rifampicin /rifabutin/carbamazepine/  est., limit.data on use in childr.theref. not recomm., use in chron./  isoniazid & phenytoin reduc. bioavail., potent. inhibit. of CYP3A4 en-
                                act.liv.dis.not recomm.
   isoniazid & phenytoin reduc.bioavail., potent.inhibit.of CYP3A4 en-  zyme incr. bioavail.,inhib. metabol. of meds.metabol.by cytochrome
   zyme incr.bioavail., inhib.metabol.of meds. metabol. by cytochrome   Side-effects: GI disturbs., psych.disturbs., CNS disturbs, paraesthes.,   3A fam. incr./prolongs their effs.
                                hypoasthes., dizzin., vertigo, malaise, fatig., skin & subcutan.tiss.
   3A fam.incr./prolongs their effs., addit.negat.inotrop.effs.with Ca
   chann. block., metabol.of Ca chan.block.inhibit sev. hypoglycaem.   disords.incl. Stev.-John.syndr.& tox.epiderm.necrolys., photosens.,   VFEND, Pfizer [P/S]
                                angioneurot.oed., psorias., hepato-bil. disords., neutropen., throm-
   with concom.oral hypoglycaem. agents. Caps also: absorpt.imp.  Voriconazole
   by reduc.gastr. acid.        bocytopen., agranulocytos., musculoskelet.disords.incl. arthralg.,   Indications: Invas.aspergillosis, ser.invas. Candida spp.(incl.C krusei)
                                myalg., cholestas., hepatit.
                                                              infects., ser. Scedosporium spp & Fusarium spp.fung.infects., prevent.
   TERBANE, Sandoz [P/S]        Special precautions: Excret.in breast milk, imp. liv./ ren.funct., dis-  of fung.infect.breakthrough in febrile high-risk pts.where liposomal
   Terbinafine HCl.             cont.in pres.of S&S indicat.of liv dysfunct., psorias.poss.exacerbat.,   amphotericin B cannot be used.
   Indications: Fung.skin infect.caus.by Trichophyton spp., Micro-  complete S&S resolut.poss.occur.only sev.wks.aft.mycologic.cure.  (S4) IV SOL.FOR INFUS, [P/S] 36/20.1.7/0108
   sporum canis & Epidermophyton floccosum, ringworm where oral   Drug interactions: Clear.acceler.by meds.which induc.metabol.,   700856-001: 200 mg, sngl.vial, R1 107,52
   ther. appropr. due to site/sev.of infect., onychomycos.  clear.inhib.by meds.which inhib. cytochrom.P-450, inhibits CYP2D6-  (S4) TABS, [P/S] 36/20.1.7/0106, 0107
   (S4) TABS, 38/20.2.2/0397    mediat. metabol.(eg.TCA’s, beta-block./SSRI’s & MAO-B inhibit.),   700832-001: 50 mg, 14, R1 386,11
   706757-001: 250 mg, 14, R312,44  menstr.disturbs.with OC’s.  700845-001: 200 mg, 28, R11 089,46
   Dosage: 250 mg once dly.     TRISPORAL, Janssen-Cilag [P/S]  Dosage: Admin.tabs.1 hr.prior/1 hr aft.meals.
   Treatm.durat.varies accord.to indicat.& sev. Tinea pedis: 2-6 wks.   Itraconazole.  IV infus: Not for bolus inj. Reconstit.& add to compat. infus.sol.to
   Tinea corporis: 4 wks., Tinea cruris: 2-4 wks. Onychomycos: 6   Indications: Reduc.incid.of ac./recurr./persist. vulvovag. candidias.&   obt.fin.sol.contain.0,5-5 mg/ml where appropr.& admin.at max.rate
   wks.-3 mnths.                prophylax.thereof when not respond.to convent.ther., dermatomy-  of 3 mg/kg/hr. over 1-2 hrs. Incompat.with 4,2% sod.bic. Durat. de-
   Contraindications: Imp.liv.funct., safety in pregn. & lactat.not   cos.not respond.to convent.ther., although proof of effic. limit. fung.  pend.on clinic.& mycologic.respon. Range from 12 wks-6 months.
   est., limit.data on use in childr. theref. not recomm., use in chron./  keratit./syst.asperigillos./candidias./ histoplasmos./sporotrichos./  Init.ther.at specif.load.dos.regim.by either IV/oral route to achieve
   act.liv.dis.not recomm.      paracocidioido-mycos. & blastomycos, onychomycos.caus.by yeasts   plasma conc.close to steady state on Day 1. On basis of high oral
   Side effects: GI disturbs., psych.disturbs., paraesthes., skin & sub-  &/ dermatophytes not respond.to other ther.  bioavail. switch betw.IV & oral admin.as indicat.
   cut.tiss.disords.incl. Stev.-John. syndr.& tox.epiderm.necrolys., pho-  (S4) CAPS, [P/S] A39/20.2.2/0617.  Adults & adolesc.12-16 yrs:
   tosens., angioneurot.oed., psorias., hepato-bil.disords., neutropen.,   708721-001: 100 mg, 4, R163,61  Load.dos: IV : 6 mg/kg 12 hrlyx24 hrs. Oral: Pts 40 kg & above: 400 mg
   thrombocytopen., agranulocytos., arthralg., myalg.  708721-002: 100 mg, 14, R572,53  12 hrly.x24 hrs. Pts.&lt;40 kg: 200 mg 12 hrly x24 hrs.
   Special precautions: Excret.in breast milk, imp. liv./ ren.funct., dis-  708721-003: 100 mg, 28, R1 144,98  Maint.dos.(aft.1  24 hrs): Breakthrough infect. prevent: IV:
                                                                      st
   cont.in pres.of S&S indicat.of liv dysfunct., psorias.poss.exacerbat.  Dosage: Admin.immed.aft.meal. Use in childr. bel.12 yrs.& elderly   3 mg/kg 12 hrly. Oral: Pts 40 kg & above: 200 mg 12 hrly. Pts.&lt;40 kg:
   Drug interactions: Clear.accelerat.by meds. which induc.metabol.,   not systemat.stud.  100 mg 12 hrly. Invas.aspergillosis, ser.Candida/ Scedosporium
   clear.inhib.by meds.which inhib. cytochrom.P-450, inhibits CYP2 D6-  Ac.& recurr.vulvovag.candidias: 200 mg morn. & even.x1day OR   & Fusarium infects: IV: 4 mg/kg 12 hrly. Oral: Pts 40 kg & above:
   mediat. metabol. (eg.TCA’s, beta-block./SSRI’s & MAO-B inhibit.),   200 mg once dly.x3 days.  200 mg 12 hrly. Pts.&lt;40 kg: 100 mg 12 hrly.
   menstr.disturbs.with OC’s.   Reduc.recurr.vag.candidias.incid: 200 mg on 1  day of men-  Dosage adjustm: If respons.inadeq.incr.IV maint. dos.to 4 mg/kg
                                                      st
   TERBI-CLEAR, Activo [P/S]    strual cycle x6 mnths.        12 hrly and oral maint.dos.may be incr.to 300 mg 12 hrly. Pts.&lt;40 kg
   Terbinafine HCl.             Dermatomycos: 200 mg dly.x7 days, OR 100 mg dly.x15 days.  incr.oral maint. dos.to 150 mg 2x/day. If pts.unable to tol.high.dos.
                                                              reduc.dos.to origin.maint.doses. Reduc.oral maint. dos.by 50 mg
   Indications: Fung.skin infect.caus.by Trichophyton, Microsporum   Plant.Tinea pedis & manus: 200 mg 2xdly.x7 days or 100 mg
   canis & Epidermophyton floccosum, ringworm where oral ther. ap-  dly.x30 days.  steps to orig.maint.dos.
                                                              Concom.phenytoin: Only if benefit outweighs risk. IV maint.dos.
   propr.due to site/sev.of infect., onychomycos.  Fung.keratit: 200 mg once dly.x21 days.  to be incr.to 5 mg/kg 12 hrly. Oral maint.dos.to be incr.from 200 mg
   (S4) TABS. 42/20.2.2/0446    Onychomycos: Confirm.diagn.from appropr.nail specimens bef.init.
   714868-001: 250 mg, 14, R337,17  treatm. Continuous treatm: 200 mg dly. x3 mnths. Pulse treatm:   to 400 mg 12 hrly and in pts.&lt;40 kg from 100 mg to 200 mg 12 hrly
                                                              Concom.efavirenz: Incr.maint.dos.to 400 mg 12 hrly. Efavirenz dos.
   Dosage: 250 mg once dly. Tinea pedis: 2-6 wks., T corporis: 4 wks,   200 mg 2xdly. x 1 wk. Pulse treatm.are separat.by 3 wk. drug-free
   T cruris: 2-4 wks. In onychomycos. treat for 6 wks.-3 mnths. Childr:   interv. Fingernail infects: 2 pulse treatm. Toe nail infects.with/  decr.to 300 mg once dly.
                                                              Childr.2-12 yrs:
   Data limit.theref. not recomm.  without fingernail involvem: 3 pulse treatm.
   Contraindications: Imp.liv.funct., safety in pregn. & lactat.not est.  Aspergillos: 200 mg once dly. x2-5 mnths.  Limit.data avail. Follow.regimen used. If child is able to swall.tabs.
                                                              admin.dos.to near.mg/kg dos.poss.using whole 50 mg tabs.
   Side effects: Freq: Dyspeps., fullness, anorex., naus., abdom.pain,   Candidas.(excl.vulvovag.): 100-200 mg once dly. x3 wks.-7 mnths.
   taste loss & disturb., jaund., cholestas., hepatit., arthralg., myalg.   Incr.dos.to 200 mg 2xdly for invasive/ disseminat.dis.  Load.dos: IV : 6 mg/kg 12 hrly.x1st 24 hrs. Oral: 6 mg/kg 12 hrly.
                                                              x1st 24 hrs.
   Less freq.: Headache, psych.disturbs., para-/hypoaesthes., dizzin.,   Histoplasmos.(excl.meningeal): 200 mg once dly.-200 mg   st
   vertigo, malaise, fatig., skin reacts.incl. Stev.- Johns. syndr./tox.epi-  2xdly./400 mg once dly.x8 mnths.  Maint.dos.(aft.1  24 hrs): IV: 4 mg/kg 12 hrly. Oral: 4 mg/kg 12 hrly.
                                                              Contraindications: Concom.CYP3A4 substrates terfenadine/
   derm.necrolys., rash, urticar., photosens., angioneurot.oed., neutrop.,   Sporotrichos: 100 mg once dly.x 3mnths.
   thrombocytopen., agranulocytos.  Paracoccidioidomycos: 100 mg once dly.x6 mnths. Data on effic.  astemizole/cisapride/pimozide & quinidine as incr.conc.may lead
   Warnings and special precautions: Imp.ren. funct., discont.  of this dos.in AIDS pts.not avail.  to QTc prolongat. & rare occur.of torsade de pointes, concom. ri-
                                                              fampicin/ carbamazepine/phenobarbital/high dos.ritonavir/ergot
   in case of S&S indicat.of hepat. dysfunct. & progress.skin rash,   Chromomycos: 100-200 mg once dly.x6 mnths.
   clear.reduc.in pre-exist. liv.dis., not recomm.in childr.due to limit.   Blastomycos: 100 mg once dly.-200 mg 2xdly. OR 400 mg once   alkaloids/sirolimus/rifabutin & St.John’s Wort, safety & effic.in
                                                              childr.&lt; 2 yrs.not est., pts.with prolong.QT syndr., meds.known.to
   data, use not recomm.in chron./act.liv.dis., psorias. poss.exacer-  dly.x 6 mnths.
   bat., excret.in breast milk., discont.if progress.skin rash/hepat.  Contraindications: Pregn.-outweigh benef./ risk in life-threat.cas.,   prolong QT interv., heredit.lact.intol./Lapp lact. defic/gluc-galactose
                                                              malabsorpt., pregn.& lactat., sev. hepat.impairm., not studied in sev.
   dysfunct.occ.                CYP3A4 metabol.HMG-COA reduct.inhibit.such as simvastin & lovas-
   Interactions: Clear.accelerat.by meds.which induc. metabol.  tatin, oral midazolam & triazolam, ergot alkaloids, nisoldipine, ven-  chron. hepat. cirrhos.
                                                              Side effects: Anaphylact.-type reacts.immed.on init.IV infus., trans.
   eg.rifampic., clear.inhibit.by meds. inhibit. cytochrome P450   tric.dysfunct. e.g.CHF or hist.thereof unless life threaten./ser.infect.,
   eg.cimetid., inhibits CYP2D6 -mediat.metabol.eg.TCA’s/beta-block./   hypersens. to other azole antifung.agents., no benef.in prophylax.of   hepat.reacts., ser.hepat.reacts. prim.with ser.underly.condits., ac.ren.
   SSRI’s & MAOI type B, menstr.irregul.with OC’s.  cryptococc.meningit.in HIV-infect. pts., concom.terfenadine/astemi-  fail., exfoliat. cutan.reacts., photosens., trans.vis.disturbs.assoc. with
                                zole/ bepridil/mizolastine/cisapride/dofetilide/ quinidine/ pimozide/  high plasma conc.incl.retin.haemorrh/corn. opacity & optic atrophy,
   TERBICIL, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  levacetylmethadol & sertindole as QT prolongat.poss., lactat., only   sinusit., allerg.reacts., fev., periph.oed., chills, asthen., chest pain, inj.
   Terbinafine HCl.             init. ther.if benef.exceeds hepat.injur.risk if liv. enzymes rais./act.liv.  site reacts./ inflammat., flu syndr., lung oed, card. arrhythm., ventric.
   Indications: Fung.skin infect.caus.by Trichophyton, Microsporum   dis./when liv.toxic.exper. with other drugs.  dysrthythm./fibrillat.incl.AV compl. block & bundle branch block, pro-
   canis & Epidermophyton floccosum ringworm where oral ther. ap-  Side effects: Ser.hepatotox., hepatit., congenit. abnormal., sev.hy-  long.QT interv., GI disturbs., abdom./back pain, pseudomembr. colit.,
   propr. due to site/sev.of infect., onychomycos.  poglycaem.with concom.oral hypoglycaem.agents, bld.dyscras., ser.  elev.LFT, jaund., cholestat. jaund., cholecystit., cholelithias., enlarg.
   (S4) TABS, A38/20.2.2/0484   sickn., angioneurot.oed., anaphylax., allerg.reacts., hypertriglyceri-  liv., hepatit., hepat.fail., adren.cortex insuffic., hyper-& hypothyroid-
   705430-001: 250 mg, 14, R479,49  daem., hypokalaem., periph. neuropathy, paraesthes., hypoaesthes.,   ism, bld.dyscras., hypokalaem., hypoglycaem., hypercholesterolae-
   Dosage: 250 mg once dly.     headache, dizzin., vis.disturbs., tinnit., CHF, pulm. oed., GI disturbs.,   mia, arthrit., headache, CNS effs., Guillain-Barre syndr., oculogyric
   Treatm.durat.varies accord.to indicat.& sev. Tinea pedis: 2-6 wks.   tox.epiderm.necrolys., Stev.-Johns.syndr., erythema multiforme, ex-  crisis, extrapyramid.syndr., hepat.coma, insomn., encephalopathy,
   Tinea corporis: 4 wks., Tinea cruris: 2-4 wks. Onychomycos: 6   foliat. dermatit., urticar., alopec., skin rash, prurit., photosens., myalg.,   somnol.dur.infus., psych. disords., resp.distress syndr., skin reacts.
   wks.-3 mnths.                arthralg., polaakiuria, urin. contin., menstr.disords., erect.dysfunct.,   incl. exfoliat. dermatit./purpura/fix.drug erupt./ Stevens-Johnson
   Contraindications: Imp.liv.funct., safety in pregn. & lactat.not   oed., adren. suppress.with high dos., negat.inotrop.eff.  syndr/erythema multiforme & toxic. epiderm.necrolys., eczema,
   est., limit.data on use in childr. theref.not recomm.,use in chron./  Special precautions: Adeq.contracept.in women of child-bear.  psorias., urticar., photosens., face oed., angioed., discoid lupus
   act. liv.dis.not recomm.     potent.until next menstr. period follow end of ther., teratogen.in lab.  erythematos., vertigo, hypoacus., tinnit., hypotens., thrombophleb.,
   Side effects: GI disturbs., CNS effs., psych. disturbs., skin reacts.incl.   anim., discont.ther.if S&S of CHF develop, hepat./ren. impairm.&   phlebit., lymphangit., ren.& urin.disords.
   Stev.-Johns.syndr.& tox. epiderm.necrolys., photosens., angioneurot.   cirrhot.pts., concom.hepatotox.meds., monit.liv.funct.in treatm., pts.  Warnings and special precautions: Monit.ren. funct., monit for
   oed., psorias., hepato-bil.disords., bld.dyscras., arthralg., myalg.  to report S&S of liv. dysfunct., incr.CHF risk with Ca Chann.block.,   devel.of pancreatit., avoid sunlight, discont.if les.progr., admin.con-
   Special precautions: Excret.in breast milk, chron. liv.dysfunct. /  monit. concom.oral anticoags./HIV protease inhibit. / cert.antineo-  com. phenytoin only if benef.outweighs risk in which case monit.lev.
   imp. ren.funct., discont.in pres. of S&S indicat.of liv.dysfunct., pso-  plast.agents eg.vinca alkaloids, busulphan, docetaxel & trimetrexate/   careful., avoid co-admin.with ritonavir unless.benef./risk justif., con-
   rias.poss. exacerbat.        CYP3A4 metabol.Ca chann.block./ immunosuppress. eg.cyclospor./  com. efavirenz admin., lact.intol., poss.prolong QT interv.without clear</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page292.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page288.html">288</a>&nbsp;&nbsp;&nbsp;<a href="page289.html">289</a>&nbsp;&nbsp;&nbsp;<a href="page290.html">290</a>&nbsp;&nbsp;&nbsp;<a href="page291.html">291</a>&nbsp;&nbsp;&nbsp;<a href="page292.html">292</a>&nbsp;&nbsp;&nbsp;<a href="page293.html">293</a>&nbsp;&nbsp;&nbsp;<a href="page294.html">294</a>&nbsp;&nbsp;&nbsp;<a href="page295.html">295</a>&nbsp;&nbsp;&nbsp;<a href="page296.html">296</a>&nbsp;&nbsp;&nbsp;<a href="page297.html">297</a>&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>
             </td>
             <td width="35%"><a href="page294.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page294.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
